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Introduction
Many infl ammatory diseases are becoming 
common in aging societies throughout the world. 
The clinically used anti-infl ammatory drugs suf-
fer from the disadvantage of side effects and high 
cost of treatment (in case of biologics). Alterna-
tives to these drugs are traditional medicines 
and natural products, which offer a great hope 
in the identifi cation of bioactive lead compounds 
and their development into drugs for treating in-
fl ammatory diseases (Gautam and Jachak, 2009). 
Many plant species and their products exhibit-
ing experimental or clinical anti-infl ammatory or 
analgesic activities have been recently reviewed 
(Anilkumar, 2010), one of the best examples be-
ing acetylsalicylic acid (aspirin) derived from the 
bark of Salix alba (Gómez Estrada et al., 2011).
Several species of the family Bromeliaceae are 
characterized by the production of proteases in 
unusually high amounts, particularly in their fruits, 
probably with a role in defence responses (Boller, 
1986; van der Hoorn and Jones, 2004). Bromelain, 
an extract rich in cysteine endopeptidases ob-
tained from Ananas comosus L. (Bromeliaceae) 
stems, has been shown to have both in vivo and 
in vitro antiedematous, anti-infl ammatory, antico-
agulant, and fi brinolytic effects and is employed 
in therapies alternative and/or complementary 
to treatments with glucocorticoids, nonsteroidal 
antirheumatics, and immunomodulators. Its low 
toxicity makes it also useful in the treatment of 
chronic infl ammation (Maurer, 2001). In thera-
peutic use, bromelain is orally administered alone 
or together with rutin and/or other enzymes such 
as trypsin, chymotrypsin, pancreatin, papain, li-
pases, and amylases (Brien et al., 2004).
The anti-infl ammatory activity of bromelain 
involves an increase in the fi brinolytic activity, 
enhancement of plasmin concentration by activa-
tion of the conversion of plasminogen to plasmin, 
decrease of the levels of plasma fi brinogen, brady-
kinin, and prekallikrein (Maurer, 2001), decrease 
of prostaglandin E2 (PGE2), thromboxane A2, and 
substance P levels (Vellini et al., 1986; Gaspani et 
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Several species of the family Bromeliaceae are characterized by the production of pro-
teases in unusual amounts, especially in fruits. Bromelain, an extract rich in cysteine endo-
peptidases obtained from Ananas comosus L., and a few other proteases have been used 
as anti-infl ammatory agents for some years, but bromelain is still mainly being used as al-
ternative and/or complementary therapy to the treatment with glucocorticoids, nonsteroi-
dal antirheumatics, and immunomodulators. In this study, the anti-infl ammatory action of a 
partially purifi ed extract from Pseudananas macrodontes (Morr.) Harms fruits (PPEPm) is 
presented, whose main components are cysteine endopeptidases. The effect of PPEPm was 
assessed in carrageenan-induced and serotonin-induced rat paw edema, as well as in the cot-
ton pellet granuloma model. Doses with equal proteolytic activity of PPEPm and bromelain 
produced signifi cantly similar anti-infl ammatory responses in the acute infl ammatory models 
assayed, supporting the hypothesis that proteolytic activity could be responsible for the 
anti-infl ammatory action. On the contrary, comparable anti-infl ammatory effects of PPEPm 
and bromelain in the chronic infl ammatory assay required a much lower proteolytic activity 
content of PPEPm, which could be due to a differential affi nity for the protein target involved 
in this process.
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al., 2002), as well as the modulation of cell surface 
molecules involved in migration (Fitzhugh et al., 
2008) and cellular activation (Hale and Haynes, 
1992; Mynott et al., 1999; Hale et al., 2002), and 
reduction of cyclooxygenase-2 (COX-2) expres-
sion by inhibing the activation of nuclear factor 
kappa-B (NF-KB) (Bhui et al., 2011). Even though 
the mechanism of the anti-infl ammatory action of 
bromelain has not yet been defi nitively elucida-
ted, its proteolytic activity appears to be implica-
ted (Fitzhugh et al., 2008; Hale and Haynes, 1992; 
Mynott et al., 1999; Hale et al., 2002, 2005). For 
fi cin and bromelain, Netti et al. (1972) found the 
degree of the inhibition of rat paw edema induced 
by different agents – carrageenan, serotonin, dex-
tran, and brewer's yeast – similar or better than 
that achieved with indomethacin, acetylsalicylic 
acid, and phenylbutazone.
Two cysteine endopeptidases, viz. macrodontain 
I and II, have been isolated from Pseudananas 
macrodontes (Morr.) Harms fruits and character-
ized by us (López et al., 2001). The N-terminal se-
quences of both proteases (including the Cys 26 
of the active site) show a high degree of identity 
(92.6%), as differences in only two residues are 
observed. Macrodontain I possesses 85.7% identi-
ty with comosain, 85.2% with stem bromelain, and 
77.8% identity with ananain, while macrodontain 
II possesses 88.9% identity with stem bromelain, 
77.8% with ananain, and 76.2% with comosain 
(López et al., 2001). The primary structure of 
macrodontain I is composed of 213 amino acids 
(UniProtKB/Swiss-Prot entry P83443; molecular 
mass, 23,486 Da), and the alignment with other 
plant cysteine peptidases revealed that the high-
est degree of identity (77%) was obtained with 
fruit bromelain, followed by ananain (71.9%), 
and stem bromelain (67.1%) (Brullo, 2003).
In this study, the anti-infl ammatory action of a 
partially purifi ed extract of P. macrodontes fruits 
(PPEPm) and its comparison with the action of 
bromelain in acute and chronic infl ammation 
models was examined.
Material and Methods
Chemicals
Bromelain (B4882), carrageenan type IV, ca-
sein (from bovine milk), Coomassie brilliant blue 
G-250, cysteine, indomethacin (> 99%), serotonin, 
and Tris were purchased from Sigma-Aldrich (St. 
Louis, MO, USA).  Ethylenediaminetetraacetic 
acid (EDTA) was purchased from Invitrogen 
(Carlsbad, CA, USA), sodium phosphate (98%) 
from Carlo Erba (Rodano, MI, Italy), ketamine 
chlorohydrate (50 mg/mL) from Holliday Scott 
(Beccar, BA, Argentina), xylazine chlorohydrate 
(10 mg/mL) from Richmond Laboratories Vet 
Pharma (Buenos Aires, Argentina), and dexa-
methasone sodium phosphate (4 mg/mL) from 
Laboratorios Klonal (Quilmes, BA, Argentina).
Plant material
Pseudananas macrodontes fruits were collected 
in Santa Ana, Department of Candelaria, Pro-
vince of Misiones, Argentina (latitude, S 27°23'; 
longitude, W 55°33'), by Prof. Aníbal G. Amat. A 
voucher specimen (Leg. Amat, No. 1596) was de-
posited at the herbarium of the Faculty of Exact, 
Chemical and Natural Sciences of the National 
University of Misiones (MNES), Misiones, Ar-
gentina. Fruits were washed with distilled water, 
dried, and stored at –20 °C until extraction.
Preparation of plant extract
Crude and partially purifi ed extracts were 
obtained according to López et al. (2000), with 
some modifi cations. Frozen unripe fruits (120 g) 
were chopped and homogenized with 600 mL of 
0.1 M sodium phosphate buffer (pH 6.0) contain-
ing 5 mM EDTA and 5 mM cysteine as protective 
agents. The homogenate was fi ltered and centri-
fuged at 5,000 x g for 30 min. The supernatant 
(crude extract) was collected, fi ltered, and stored 
at –20 °C until use. Then, to one volume of crude 
extract one volume of cold (–20 °C) 96% ethanol 
was added during 30 min at 0 °C and the mixture 
centrifuged at 12,000 x g for 30 min. The precipi-
tate was discarded, and three volumes of cold 
ethanol were added to the supernatant during 2 h 
at 0 °C; the resulting mixture was centrifuged at 
12,000 x g for 30 min. The ethanol precipitate was 
redissolved in 0.1 M sodium phosphate buffer (pH 
6.0) after evaporation of the solvent in vacuo. Fi-
nally, the partially purifi ed extract, named PPEPm, 
was lyophilized and stored at –20 °C.
Extract characterization
Assays on caseinolytic activity (1% casein, 
0.1 M Tris-HCl buffer, pH 7.5, 37 °C, 2 min) were 
carried out to determine the proteolytic activity 
of PPEPm. An arbitrary enzyme unit (caseinolytic 
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unit, CU) was used to express the proteolytic ac-
tivity (López et al., 2000).The protein content was 
determined by the method of Bradford (1976), 
using bovine serum albumin as standard.
Animals
Wistar albino rats were purchased, housed, and 
cared for at the Animal Resource Facilities, Facul-
ty of Chemistry, Biochemistry and Pharmacy, Na-
tional University of San Luis, San Luis, Argentina. 
The experimental protocols were approved by the 
Laboratory Animal Care and Use Institutional 
Committee in compliance with Argentine offi cial 
resolutions for animal care guidelines (ANMAT 
No. 6344/96). Animals were randomly assigned to 
different groups (n = 6), provided with standard 
rodent chow diet (Cooperación, Buenos Aires, 
Argentina) and water ad libitum, and maintained 
at a constant temperature of (24  1) °C and a 
humidity of (55  5)% under a 12-h light/12-h 
dark cycle.
Drug administration
PPEPm doses were prepared by dissolving the 
lyophilized powder in sterile water. The dose of 
bromelain was prepared by dissolving the com-
mercial material in 0.1 M sodium phosphate buff-
er (pH 6.0). All doses (0.5 mL) were administered 
intraperitoneally (i.p.).
Carrageenan-induced paw edema in rats
Anti-infl ammatory activity was assessed on 
paw edema induced by carrageenan, following 
the method described by Winter et al. (1962). 
Male Wistar rats, weighing 170 – 220 g, were di-
vided into fi ve groups (n = 6): two groups re-
ceived PPEPm [90 and 180 mg/kg body weight 
(BW)], the control group received 0.1 M sodium 
Fig. 1. Model design and dosing routines for rats in (A) carrageenan-induced paw edema, (B) serotonin-induced 
paw edema, and (C) cotton pellet-induced granuloma.
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phosphate buffer (pH 6.0), one of the reference 
groups received indomethacin (10 mg/kg BW), 
and the other one received bromelain (50 mg/kg 
BW). One h later, 0.1 mL of 2% (w/v) carrageen-
an type IV suspended in saline was injected into 
the subplantar region of the left hind paw of each 
rat. Volumes of both hind paws were measured 
in triplicate using a plethysmograph (Ugo Basile, 
Varese, Italy) at 1, 3, 5, and 7 h after injection of 
carrageenan (Fig. 1A). The edema volume was 
expressed as the difference between the average 
volumes of the two hind paws. The inhibition per-
centage of edema was calculated for each group 
in comparison with the control group as (1 – Vt/
Vc) · 100, where Vc and Vt are the edema average 
volumes of control and treated groups, respec-
tively.
Serotonin-induced paw edema in rats
Male Wistar rats, weighing 200 – 220 g, were 
divided into three groups (n = 6): one group re-
ceived PPEPm (180 mg/kg BW), the control group 
received 0.1 M sodium phosphate buffer (pH 
6.0), and the reference group received bromelain 
(50 mg/kg BW). One h after drug administra-
tion, all groups received a subplantar injection of 
0.1 mL of 0.01% serotonin solution in normal sa-
line (Kalbhem and Smalla, 1977). Edema volume 
was measured at 30, 60, and 120 min after injec-
tion of serotonin following the same procedure 
used in the carrageenan-induced edema method 
(Fig. 1B). Percent inhibition of edema was calcu-
lated as mentioned above.
Cotton pellet-induced granuloma in rats
The assay was carried out following the method 
of Meier et al. (1950). Female Wistar rats, weigh-
ing 115 – 150 g, were anaesthetized by i.p. injection 
of a mixture of ketamine chlorohydrate (75 mg/
kg BW) and xylazine chlorohydrate (12 mg/kg 
BW). Granuloma was induced in all animals by 
a subcutaneous implant of a sterile cotton pellet 
(50 mg) in the dorsal area. One d later, animals 
were divided into four groups and i.p. inoculated 
once daily during 6 d as follows: one group re-
ceived PPEPm (60 mg/kg BW), the control group 
received 0.1 M sodium phosphate buffer (pH 6.0), 
one reference group received bromelain (50 mg/
kg BW), and the other one dexamethasone (4 mg/
kg BW). On day 7, body weight was recorded, and 
the animals were sacrifi ced by cervical dislocation. 
The pellets surrounded by granuloma tissue were 
removed and weighed. Spleen and thymus were 
dissected out and weighed. The anti-infl ammatory 
effect was assessed by determining the inhibition 
percentage of granuloma formation in the groups 
under study as compared with the control as fol-
lows: (1 – mt/mc) · 100, where mc and mt are the 
average weights of control and treated groups, re-
spectively. Reduction percentage of thymus and 
spleen weights was calculated with the same for-
mula. Body weight change was calculated as the 
difference between fi nal and initial body weights. 
Fig. 1C shows model design and dosing routines.
Statistical analysis
The GraphPadPrism software version 5.0 was 
used for statistical analysis. Data obtained are 
presented as mean  SEM. Raw data (edema 
volume and weights) were analysed with Oneway 
ANOVA followed by Tukey's Multiple Compari-
son test. A probability of p < 0.05 was considered 
signifi cant.
Results and Discussion
The protein content of the partially purifi ed 
extract obtained from Pseudananas macrodontes 
fruits (PPEPm) was (28  2) μg/mg of lyophilized 
powder, and its specifi c enzymatic activity was 
(5.6  0.4) CU/mg of protein (37 °C, pH 7.5). In 
the case of stem bromelain (B4882), the pro-
tein content was (200  12) μg/mg of commer-
cial powder, and specifi c enzymatic activity was 
(3.2  0.2) CU/mg of protein (37 °C, pH 7.5).
Edema formation is one the events that happen 
during acute infl ammatory response and is the re-
sult of changes in the microvasculature of the in-
fl amed area. Carrageenan-induced rat paw edema 
is a model of acute infl ammation widely used to 
determine the anti-infl ammatory activity of drugs, 
and doses of nonsteroidal anti-infl ammatory drugs 
(NSAIDs) in this test correlated well with effec-
tive doses in patients (Morris, 2003). Table I shows 
the effects of PPEPm (90 and 180 mg/kg BW), bro-
melain (50 mg/kg BW), and indomethacin (10 mg/
kg BW) administration on carrageenan-induced 
paw edema in rats. Both PPEPm doses elicited an 
anti-infl ammatory effect: the lower one (90 mg/
kg BW) signifi cantly inhibited edema formation 
after 3 h, reaching maximum relative inhibition 
(about 45%) between 3 and 5 h after carrageenan 
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administration, while the higher one (180 mg/kg 
BW) inhibited after 1 h, reaching the maximum 
effect (about 80%) between 5 and 7 h after car-
rageenan administration. Bromelain was signifi -
cantly anti-infl ammatory after 3 h and exhibited 
maximum inhibition (about 75%) after 5 h of car-
rageenan administration. Indomethacin showed 
signifi cant anti-infl ammatory activity 5 and 7 h 
after carrageeenan administration.
Edema development in this model has been 
described as a biphasic process (Vinegar et al., 
1969; Salvemini et al., 1996). The initial phase 
of edema formation (0 – 1 h), which is not inhi-
bited by NSAIDs, is attributed to the release of 
histamine and serotonin (Di Rosa et al., 1971). 
The second phase (1 – 6 h) is associated with a 
local infi ltration and activation of neutrophils 
(Boughton-Smith et al., 1993) and the production 
of prostaglandins (Di Rosa et al., 1971), which 
has been attributed to the induction of COX-2 
( Nantel et al., 1999). An increase in NO produc-
tion is also associated with the increase of paw 
volume (Salvemini et al., 1996).
Although PPEPm (180 mg/kg BW) had a signifi -
cant anti-infl ammatory effect from the fi rst hour 
after injection of carrageenan, the maximum inhi-
bition was reached 5 h after carrageenan admin-
istration, as in the case of bromelain and indo-
methacin. All doses tested produced signifi cant 
inhibition after 7 h. It is known that indomethacin 
inhibits prostaglandins production (by inhibition 
of COX-1), while bromelain, in other experimen-
tal models, has been shown to reduce the produc-
tion of NO (Wen et al., 2006) and prostaglandins 
(Bhui et al., 2011), as well as neutrophil migra-
tion (Fitzhugh et al., 2008). These results allow us 
to conclude that PPEPm acts preferentially on the 
second rather than the fi rst phase of carrageenan-
induced edema, which could be explained by a 
better bioavailability and/or increased specifi city 
against the release/action of mediators involved 
in the second phase (neutrophils, prostaglandins, 
and NO), whose production usually peaks be-
tween 3 and 6 h after injection of carrageenan 
(Salvemini et al., 1996).
Table I. Effect of PPEPm, bromelain, and indomethacin on carrageenan-induced paw edema in rats.
Time
[h]
Control PPEPm
[90 mg/kg BW =
(15  1) CU/kg BW]
PPEPm
[180 mg/kg BW =
(31  2) CU/kg BW]
Bromelain
[50 mg/kg BW =
(32  2) CU/kg BW]
Indomethacin
(10 mg/kg BW)
Edema 
volume 
[mL]
Edema 
volume 
[mL]
Inhibition 
(%)
Edema 
volume 
[mL]
Inhibition 
(%)
Edema 
volume 
[mL]
Inhibition 
(%)
Edema 
volume 
[mL]
Inhibition 
(%)
1 0.27  0.03 0.19  0.02 29bc 0.12  0.02 55b*** 0.18  0.02 33bc 0.24  0.02 11c
3 0.64  0.07 0.35  0.04 45ba** 0.19  0.02 70b*** 0.29  0.03 55b*** 0.55  0.06 14ca
5 1.14  0.08 0.6  0.2 47b** 0.23  0.02 80b*** 0.28  0.02 75b*** 0.38  0.03 67b***
7 1.3  0.1 0.8  0.2 38a* 0.20  0.02 85b*** 0.45  0.04 65d*** 0.55  0.04 58ad***
Edema volumes are expressed as the mean  SEM (n = 6). Inhibition (%) represents the mean percentage reduc-
tion in paw volume relative to controls. Tukey's test: *p < 0.05, **p < 0.01, ***p < 0.001 compared to the control 
group; the means with a common subscript letter are not signifi cantly different at p < 0.05.
Table II. Effect of PPEPm and bromelain on serotonin-induced paw edema in rats.
Time 
[min]
Control PPEPm
[180 mg/kg BW =
(31  2) CU/kg BW]
Bromelain
[50 mg/kg BW =
(32  2) CU/kg BW]
Edema
volume [mL]
Edema
volume [mL]
Inhibition
(%)
Edema
volume [mL]
Inhibition
(%)
30 1.05  0.07 0.75  0.11 29a* 0.52  0.03 50a***
60 0.87  0.07 0.68  0.12 22ca 0.50  0.04 42a*
120 0.67  0.06 0.56  0.11 20c 0.46  0.04 31c
Edema volumes are expressed as the mean  SEM (n = 6). Inhibition (%) represents the mean percentage re-
duction in paw volume relative to controls. Tukey's test: *p < 0.05, ***p < 0.001 compared to the control group; 
the means with a common subscript letter are not signifi cantly different at p < 0.05.
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To evaluate the action of PPEPm on the early 
development of edema, the serotonin-induced 
edema assay was carried out. Table II shows the 
results of PPEPm (180 mg/kg BW) and bromelain 
(50 mg/kg BW) administration on serotonin-
induced paw edema in rats. PPEPm signifi cantly 
inhibited edema formation (29%) 30 min after 
serotonin injection, which was not signifi cantly 
different from the action of bromelain (50%). 
Also, bromelain exhibited signifi cant anti-infl am-
matory activity (42%) 60 min after injection.
Granulomatous infl ammation is a morpho-
logical type of chronic state of infl ammation, and 
the cotton pellet-induced granuloma in rats is a 
representative model for studying drugs against 
this infl ammation phase (Bailey et al., 1982). An-
ti-infl ammatory action of PPEPm was assayed in 
this model and compared with that of bromelain 
and dexamethasone. PPEPm (60 mg/kg BW) and 
bromelain (50 mg/kg BW) were similarly effec-
tive in the cotton pellet-induced granuloma assay 
(Fig. 2). PPEPm, bromelain, and dexamethasone 
(4 mg/kg BW) signifi cantly reduced granuloma 
formation relative to the control at day 7, in-
hibiting 26, 24, and 54%, respectively. Values for 
PPEPm and bromelain were not signifi cantly dif-
ferent from each other, but were signifi cantly 
lower than that for dexamethasone. In addition, 
some side effects, common to long-term glucocor-
ticoid therapy, were evaluated: the immunosup-
pressive action, by weighing thymus and spleen 
(Ben Rhouma and Sakly, 1994; Hori et al., 1996), 
and the catabolic effect, by measuring the loss of 
body mass. While dexamethasone caused signifi -
cant atrophy of spleen and thymus (50 and 86%, 
respectively), bromelain and PPEPm only reduced 
thymus weight to the same low degree (26%). 
On the other hand, changes in body weight in the 
control group and those treated with PPEPm and 
bromelain were not signifi cantly different. Body 
weight increments at the end of the assay were 
15 g for the control group, and 17 and 15 g for 
PPEPm- and bromelain-treated groups, respective-
ly. In contrast, dexamethasone produced a signifi -
cant body weight loss (–11 g).
These results are promising for the application 
of proteolytic preparations in the long-term treat-
ment of chronic diseases; however, toxicological 
tests are required to confi rm this view. Sixty mg 
PPEPm/kg BW was the dose of choice, because 33% 
mortality was observed with a dose of 180 mg/kg 
BW (data not shown). On the other hand, taking 
into account the predominant role of T-cells in the 
development of granulomatous infl ammation (Co 
et al., 2004) and the slight thymic atrophy that ac-
companies the inhibition of granuloma formation 
by PPEPm and bromelain, also observed for Bro-
melia hieronymi extracts (Errasti et al., 2013), one 
might assume that part of the anti-infl ammatory 
action involves the regulation of T-cell activity.
Since the anti-infl ammatory mechanism of 
bromelain has been attributed to its proteolytic 
activity (Fitzhugh et al., 2008; Hale and Haynes, 
1992; Mynott et al., 1999; Hale et al., 2000, 2005), 
the higher dose of PPEPm (on weight basis) in the 
acute infl ammatory assays was chosen to contain 
proteolytic activity equal to that of bromelain 
( 30 CU/kg BW). The observation that, on this 
basis, the effects of the two preparations were 
signifi cantly similar, supports the notion that pro-
teases are responsible for their anti-infl ammatory 
activities. On the contrary, a much lower dose 
of PPEPm [(10  1) CU/kg BW] was suffi cient to 
produce an anti-infl ammatory effect comparable 
to that of bromelain (32  2 CU/kg BW) in the 
chronic infl ammatory assay, which could be due 
to differential affi nities for the protein(s) criti-
cally involved in the latter process.
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